1.Age-period-cohort analysis of hepatitis A incidence rates in Korea from 2002 to 2012.
Joo Yeon SEO ; Sungyong CHOI ; BoYoul CHOI ; Moran KI
Epidemiology and Health 2016;38(1):e2016040-
OBJECTIVES: This study aimed to evaluate the epidemiology of hepatitis A in Korea from 2002 to 2012 using age-period-cohort analyses. METHODS: We used claims data from the Korean National Health Insurance Corporation for the entire population. Census data from 2010 were used as the standard population. The incidence of hepatitis A was assumed to have a Poisson distribution, and the models and effects were evaluated using the intrinsic estimator method, the likelihood ratio, and the Akaike information criterion. RESULTS: The incidence of hepatitis A gradually increased until 2007 (from 17.55 to 35.72 per 100,000 population) and peaked in 2009 (177.47 per 100,000 population). The highest incidence was observed among 27-29-year-old individuals when we omitted data from 2005 to 2007. From 2005 to 2007, the peak incidence was observed among 24-26-year-old individuals, followed by 27-29-year-olds. The best model fits were observed when the age-period-cohort variables were all considered at the same time for males, females, and the whole population. CONCLUSIONS: The incidence of hepatitis A exhibited significant age-period-cohort effects; its incidence peaked in 2009 and was especially high among Koreans 20-39 years of age. These epidemiological patterns may help predict when high incidence rates of hepatitis A may occur in developing countries during their socioeconomic development.
Censuses
;
Developing Countries
;
Epidemiology
;
Female
;
Hepatitis A*
;
Hepatitis*
;
Humans
;
Incidence*
;
Korea*
;
Male
;
Methods
;
National Health Programs
2.A Phase II Trial of Neoadjuvant Chemotherapy with Genexol(R) (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer.
Jinsun LEE ; Jeryong KIM ; Eilsung CHANG ; Woonjung CHOI ; Kwangman LEE ; Hyunjo YOON ; Sunghoo JUNG ; Minho PARK ; Junghan YOON ; Sungyong KIM
Journal of Breast Cancer 2014;17(4):344-349
PURPOSE: Neoadjuvant chemotherapy (NC) is yet to be established as the definitive treatment regimen for locally advanced breast cancer (LABC). The aim of this study was to determine the efficacy and toxicity of NC with epirubicin and paclitaxel. METHODS: Between March 2007 and January 2009, 50 patients with LABC were enrolled in an open-label, phase II, multicenter study carried out at five distinct institutions. All patients were scheduled to receive four cycles of 60 mg/m2 epirubicin and 175 mg/m2 paclitaxel every 3 weeks, preoperatively, unless they developed profound side effects or disease progression. After curative surgery, two additional cycles of chemotherapy were administered to patients who had shown a positive response to NC. RESULTS: In all, 196 cycles of chemotherapy were administered preoperatively; 47 of the 50 patients (94%) underwent all four cycles of designated treatment. Complete disappearance of invasive foci of the primary tumor, and negative axillary lymph nodes were confirmed in eight patients (16.0%), post operation. The cumulative 5-year disease-free survival rate was 70.0% for patients with complete remission (CR) and partial remission (PR), and 33.3% for patients with stable disease (SD) and progressive disease (PD) (p=0.018). The cumulative 5-year overall survival was 90.0% for patients who achieved CR and PR and 55.6% for patients who had SD and PD (p=0.001). Neutropenia (42.0%) was the most common grade 3/4 toxicity. However, none of the toxicities resulted in cessation of the treatment. CONCLUSION: The encouraging pathologic response observed in the patients treated with epirubicin plus paclitaxel NC in this study suggests that epirubicin could be a substitute for doxorubicin, which is the most cardiotoxic agent.
Breast Neoplasms*
;
Disease Progression
;
Disease-Free Survival
;
Doxorubicin
;
Drug Therapy*
;
Epirubicin*
;
Humans
;
Lymph Nodes
;
Neoadjuvant Therapy
;
Neutropenia
;
Paclitaxel